FDA Brief

Warning letters Drugs

FDA warning letter to

Dunagin Pharmaceuticals Inc. dba Massco Dental

High riskIssued Feb 22, 2023Posted Mar 21, 2023Division of Pharmaceutical Quality Operations II

Dunagin Pharmaceuticals dba Massco Dental made oral drugs with CGMP violations including shared equipment and inadequate component testing.

What happened

FDA inspected Dunagin Pharmaceuticals Inc. dba Massco Dental at its Rogers, AR facility from August 29 to September 2, 2022, and found significant CGMP violations for finished drugs. The inspection found drugs, including fluoride and potassium nitrate toothpastes and mouth rinses, were made on equipment shared with nonpharmaceutical materials; the firm relied on supplier certificates without establishing their reliability and lacked diethylene glycol and ethylene glycol (DEG/EG) testing for glycerin. FDA also found no process validation, poor equipment maintenance, inadequate quality unit oversight of out-of-specification results, and an inadequate water system.

What FDA found

  1. The firm made drugs on the same equipment used for nonpharmaceutical materials and lacked separate or defined areas to prevent contamination or mix-ups.

    21 CFR 211.42(c)
  2. The firm relied on supplier certificates of analysis without establishing their reliability, used nonpharmaceutical grade potassium nitrate, and did not test all glycerin shipments for diethylene glycol and ethylene glycol.

    21 CFR 211.84(d)(2)
  3. The firm did not validate its manufacturing processes and did not adequately maintain mixing equipment that had rust and chipping paint.

    21 CFR 211.100(a)
  4. The quality unit failed to investigate out-of-specification results, which were discarded and retested, and the firm did not perform required stability testing or periodic evaluations.

    21 CFR 211.22(a)
  5. The firm lacked adequate laboratory controls for its water system and finished product testing, including no chemical water analysis and insufficient evidence that its water and test methods met appropriate standards.

    21 CFR 211.160(b)

What FDA wants

FDA asks the company to stop making drugs on shared equipment or provide a plan for dedicated separate equipment, and to provide risk assessments and comprehensive remediation plans for component testing, process validation, quality unit/OOS investigations, stability, change management, water system, and laboratory controls. The provided letter does not state a response deadline.

Who should pay attention

  • companies that buy or distribute Massco Dental oral drug products
  • contract manufacturers that share equipment with nonpharmaceutical products
  • quality teams responsible for glycerin supplier testing and water systems

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Signature Formulations LLC

    FDA warns Signature Formulations about contaminated contract-manufactured drug products and cross-contamination at its Phoenix facility.

    High risk
  2. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium
  3. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  4. Thomas Brunner Hygiene GmbH

    Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

    High risk